Akeso shares plunge 31.8% after FDA rejects ivonescimab application
Published 3 h ago2 sourcesEvidence: Reported
The FDA rejected Summit Therapeutics' Ivonescimab, a cancer drug developed in China, marking a significant setback for Beijing's biotech ambitions. The rejection raises uncertainty about the drug's approval path and the broader viability of Chinese-origin medicines in the US market. This outcome could dampen cross-border biotech partnerships and affect investor sentiment toward Chinese biotech firms.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Locations
Entities
Published 3 h ago2 sourcesEvidence: Reported
Published 10 h ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 17 h ago2 sourcesEvidence: Reported
Published 22 h ago1 sourceEvidence: Unknown
Published 2 d ago6 sourcesEvidence: Reported
Published 15 h ago13 sourcesEvidence: Unknown
Published 7 h ago16 sourcesEvidence: Reported